M.B.A

EQS-News: MGI – Media and Games Invest SE Proposal from MGI’s Nomination Committee (M8G)

Retrieved on: 
Freitag, Mai 10, 2024
Remco, Huffington, Business, MGI, Advertising, Guideline, Economics, Person, Oaktree Capital Management, Georgetown University, EVP, Business administration, Global Media, CBS, Committee, AOL, University, M.B.A, HuffPost, Entrepreneur in residence, Marketing, Yahoo!, Synovate, P&L, BuzzFeed, Management

former CEO Global Media at Dentsu, an expert in the advertiser and media agency landscape.

Key Points: 
  • former CEO Global Media at Dentsu, an expert in the advertiser and media agency landscape.
  • Greg Coleman's extensive background and expertise, particularly in media and ad tech, make him an extremely valuable candidate for the MGI board.
  • The Nomination Committee extends its sincere appreciation to Mary Ann Halford for her invaluable contributions during her tenure on the Board of Directors.
  • The Nomination Committee's motivated statement, together with the Nomination Committee's other proposals, will be published prior to the annual general meeting on 13 June 2024.

MGI – Media and Games Invest SE Proposal from MGI’s Nomination Committee

Retrieved on: 
Freitag, Mai 10, 2024
Remco, Huffington, Business, MGI, Advertising, Guideline, Economics, Person, Oaktree Capital Management, Georgetown University, EVP, Business administration, Global Media, CBS, Committee, AOL, University, M.B.A, HuffPost, Entrepreneur in residence, Marketing, Yahoo!, Synovate, P&L, BuzzFeed, Management

former CEO Global Media at Dentsu, an expert in the advertiser and media agency landscape.

Key Points: 
  • former CEO Global Media at Dentsu, an expert in the advertiser and media agency landscape.
  • Greg Coleman's extensive background and expertise, particularly in media and ad tech, make him an extremely valuable candidate for the MGI board.
  • The Nomination Committee extends its sincere appreciation to Mary Ann Halford for her invaluable contributions during her tenure on the Board of Directors.
  • The Nomination Committee's motivated statement, together with the Nomination Committee's other proposals, will be published prior to the annual general meeting on 13 June 2024.

Denis and Davor Poljak of Poljak Group Wealth Management Ranked as Forbes 2024 "Best-in-State Wealth Advisors"

Retrieved on: 
Montag, Mai 6, 2024
M.B.A, Dream, Research, Poljak, Quality of life, Telephone

SHREVEPORT, La., May 6, 2024 /PRNewswire/ -- Poljak Group Wealth Management at Steward Partners has announced the selection of wealth managers and partners Denis Poljak, Ph.D., CPM®, CFP® and Davor Poljak, M.B.A. and CPM® to the Forbes "Best-In-State Wealth Advisors" list for 2024.

Key Points: 
  • SHREVEPORT, La., May 6, 2024 /PRNewswire/ -- Poljak Group Wealth Management at Steward Partners has announced the selection of wealth managers and partners Denis Poljak, Ph.D., CPM®, CFP® and Davor Poljak, M.B.A. and CPM® to the Forbes "Best-In-State Wealth Advisors" list for 2024.
  • The Poljak brothers, co-founders and principals of Poljak Group Wealth Management, have been recognized on the Forbes "Best-In-State Wealth Advisors" list several times for best-in-class excellence in the wealth management industry for Louisiana.
  • Denis was honored by Forbes in 2019, 2020, 2021 and 2023, and this is Davor Poljak's second year on the list, having been previously recognized in 2021.
  • Poljak Group Wealth Management is a team at Steward Partners.

Garry Menzel joins GHO Capital as Operating Partner

Retrieved on: 
Dienstag, April 23, 2024
Diamond, Credit Suisse, Doctor of Philosophy, Goldman Sachs, Stanford University, University, DSM-IV codes, Partner, ADAP, M.B.A, Immunotherapy, Molecular biology, Patient, Operating partner, GHO, Clinical trial, Therapy, Health, Biotechnology, Head, Pharmaceutical industry

London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner.

Key Points: 
  • London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner.
  • As Operating Partner, Garry will leverage his extensive biotech industry experience in building innovative businesses to guide the GHO portfolio to deliver market leading services to the emerging biopharma space, as well as supporting GHO with deal origination across Europe and the US.
  • On behalf of the entire GHO team, we wish him a warm welcome.”
    Commenting on his new appointment, Garry Menzel, Operating Partner at GHO Capital, said: “Throughout my career, I have been committed to bringing forward the highest possible innovative standards for patients within the healthcare system whilst creating long-term investor value.
  • I am excited to support GHO Capital, as Europe’s leading healthcare specialist private equity firm, to pursue the same goal.

Garry Menzel joins GHO Capital as Operating Partner

Retrieved on: 
Dienstag, April 23, 2024
Diamond, Credit Suisse, Doctor of Philosophy, Goldman Sachs, Stanford University, University, DSM-IV codes, Partner, ADAP, M.B.A, Immunotherapy, Molecular biology, Patient, Operating partner, GHO, Clinical trial, Therapy, Health, Biotechnology, Head, Pharmaceutical industry

London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner.

Key Points: 
  • London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner.
  • As Operating Partner, Garry will leverage his extensive biotech industry experience in building innovative businesses to guide the GHO portfolio to deliver market leading services to the emerging biopharma space, as well as supporting GHO with deal origination across Europe and the US.
  • On behalf of the entire GHO team, we wish him a warm welcome.”
    Commenting on his new appointment, Garry Menzel, Operating Partner at GHO Capital, said: “Throughout my career, I have been committed to bringing forward the highest possible innovative standards for patients within the healthcare system whilst creating long-term investor value.
  • I am excited to support GHO Capital, as Europe’s leading healthcare specialist private equity firm, to pursue the same goal.

ArriVent Appoints Kristine Peterson to its Board of Directors

Retrieved on: 
Montag, April 22, 2024
University, Cancer, Biovail, M.B.A, Amarin Corporation, Johnson & Johnson, Therapy, Senior, Bristol Myers Squibb, Patient, ImmunoGen, Champaign–Urbana metropolitan area, Lung cancer, Management

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors.

Key Points: 
  • NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors.
  • Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals.
  • “We are thrilled for Kris to join our Board of Directors at such an important time for ArriVent, as we advance the development of firmonertinib in multiple non-small cell lung cancer (“NSCLC”) indications,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent.
  • Earlier in her career, Ms. Peterson spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit.

CONMED Corporation Promotes Patrick Beyer to Chief Operating Officer

Retrieved on: 
Mittwoch, April 24, 2024
Surgery, Health, Medical Devices, International, M.B.A, Kalamazoo College, Patient, Physician, Advanced Management Program, Economics, Harvard University, Nursing

CONMED Corporation (NYSE: CNMD) today announced that Patrick Beyer, President of International and Global Orthopedics, has been promoted to the newly created role of Chief Operating Officer (COO), effective immediately.

Key Points: 
  • CONMED Corporation (NYSE: CNMD) today announced that Patrick Beyer, President of International and Global Orthopedics, has been promoted to the newly created role of Chief Operating Officer (COO), effective immediately.
  • In this role, Mr. Beyer will take on additional responsibility for leading the Company’s commercial businesses, as well as Operations, Distribution, Regulatory Affairs / Quality Assurance, and Customer Excellence.
  • “Pat has been invaluable in driving CONMED’s above-market growth and expanding our presence in key markets,” commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer.
  • Prior to CONMED, Mr. Beyer spent 21 years at Stryker in leadership roles of increasing progression and nearly four years as CEO of ICNet International.

Cytonus Therapeutics Expands C-suite as it Transitions to a Clinical Stage Company

Retrieved on: 
Montag, April 22, 2024
Health, Infectious Diseases, Health Technology, General Health, Pharmaceutical, Biotechnology, Doctor of Philosophy, Administration, University, LEGO, Information, Master of Business Administration, M.B.A, Intellectual property, Commercialization, Partnering, McKinsey & Company, Business administration, Corporate development, Duke University, Senior, Patent, Bachelor of Arts, Virginia Tech, Medical school, Physician, Therapy, Management

Cytonus Therapeutics, Inc., a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, announced today that Mickey Kim, M.D., M.B.A. has joined the company as Chief Business Officer.

Key Points: 
  • Cytonus Therapeutics, Inc., a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, announced today that Mickey Kim, M.D., M.B.A. has joined the company as Chief Business Officer.
  • In addition, Cytonus has added Sherry M. Carty, Ph.D., as Director of Intellectual Property and Karen Markham has been promoted to Chief Administrative Officer.
  • Prior to Inova, he was a member of MedImmune/AstraZeneca's Partnering & Strategy Leadership Team, a healthcare venture capitalist and a strategy consultant with McKinsey and Company.
  • Mrs. Markham has been promoted to Chief Administrative Officer at Cytonus, where she oversees all administrative functions.

ClearSign Technologies Corporation Appoints David Maley to Board of Directors

Retrieved on: 
Mittwoch, April 24, 2024
Goldman Sachs, University, University of Notre Dame, Partner, BMO Harris Bank, Safety, M.B.A, Research, Business, David G. Booth, Senior, Ariel, CLIR, Ariel Investments, Audit, Investment

TULSA, Okla., April 24, 2024 /PRNewswire/ -- ClearSign Technologies Corporation (Nasdaq: CLIR) ("ClearSign" or the "Company"), an emerging leader in industrial combustion and sensing technologies that improve energy and operational efficiency, and safety while dramatically reducing emissions, today announces that David Maley has been appointed to its Board of Directors (the "Board") to fill the independent director vacancy in the Board and to the Board's Audit & Risk Committee.

Key Points: 
  • TULSA, Okla., April 24, 2024 /PRNewswire/ -- ClearSign Technologies Corporation (Nasdaq: CLIR) ("ClearSign" or the "Company"), an emerging leader in industrial combustion and sensing technologies that improve energy and operational efficiency, and safety while dramatically reducing emissions, today announces that David Maley has been appointed to its Board of Directors (the "Board") to fill the independent director vacancy in the Board and to the Board's Audit & Risk Committee.
  • David Maley brings forty years of broad investment experience with more than half of that period focused on micro-cap equity research and portfolio management.
  • Mr. Maley currently serves as the Chief Investment Officer and Chief Compliance Officer of 1102 Partners, LLC, a family office and investment advisory firm founded by Mr. Maley in 2021.
  • "I am very pleased to welcome David Maley to ClearSign's Board of Directors," said Jim Deller, Ph.D., Chief Executive Officer of ClearSign.

EQS-News: Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Retrieved on: 
Mittwoch, April 10, 2024
Research, Conference, Biotechnology, M.B.A, Nikko Hotels, Multiple sclerosis, PST, RSVP

NEW YORK, April 4, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April:

Key Points: 
  • NEW YORK, April 4, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April:
    April 9: Immunic’s MS R&D Day.
  • The MS R&D Day will take place on Tuesday, April 9, 2024, from 10:30 am to 12:30 pm PST in-person at the Hotel Nikko in San Francisco.
  • Dr. Vitt will participate in a fireside chat and one-on-one investor meetings at this virtual conference.
  • A webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .